ROCKET ONE INC (RKTO)
NASDAQHealth CareSoftware - InfrastructureSnapshot 2026-09-04
$0.69+0.51%
Close 2026-09-04 · 1-day change
NASDAQHealth CareSoftware - InfrastructureSnapshot 2026-09-04
QuarterlyIQ Insights · RKTO
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Advance the nanomagnetic matrix multiplier technology for ultra-low-power AI compute acceleration through exclusive licenses, research, and prototype development.
Newly stated in 2026-Q2. Management emphasizes development of the nanomagnetic AI compute platform via exclusive licenses and research. Financials show continued operating losses and negative cash flow, with operating income at -$3.83M in 2026-Q2, reflecting early-stage investment. The trajectory is consistent with early development and no revenue yet.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Rocket One is building nanomagnetic AI compute platform through exclusive licensed IP and advancing device simulation and chip architecture modeling.”
Advance skyrmion-mediated spintronic memory for non-volatile, radiation-hard applications through exclusive licenses and sponsored research.
Newly stated in 2026-Q2. Management focuses on developing radiation-tolerant spintronic memory technology via exclusive licenses and research. Financials show ongoing losses with operating income at -$3.83M in 2026-Q2, consistent with early-stage R&D investment. The trajectory aligns with initial development efforts.
“Rocket One holds exclusive licenses for skyrmion spintronic memory and is advancing experimental device characterization.”
Build and commercialize an autonomous swarm defense platform using acquired swarm-coordination technology and AI threat emulation.
Newly stated in 2026-Q2. Management highlights acquisition of swarm-coordination technology and patent filings for autonomous swarm defense. Financials show continued operating losses (-$3.83M operating income in 2026-Q2), reflecting early-stage platform development. The trajectory is consistent with initial commercialization efforts.
“Rocket One acquired swarm-coordination assets and filed provisional patents for autonomous swarm defense platform.”
Continue raising capital through ATM equity offerings to support development and operations, with multiple increases in offering limits in 2026.
Stated in 3 of last 3 quarters. Management increased ATM equity offering limits by $2.7M in 2026-Q1, $6.8M in 2026-Q2, and $5.3M in 2026-Q2 to raise capital. Financials show ongoing negative operating income (-$3.83M in 2026-Q2) and negative cash flow, consistent with capital needs. The trajectory shows active capital raising to support operations.
“Increased ATM offering price limit by $5.3M in July 2026 to support capital raising.”
“Increased ATM offering price limit by $6.8M in June 2026 to support capital raising.”
“Increased ATM offering price limit by $2.7M in May 2026 to support capital raising.”
Over the trailing year it converted 1.06x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
22 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.